Cannabis Report: Record profits, lawsuits, and acquisitions, oh my!
Click here for the full story.
1 | Xebra Brands announces letter of intent to acquire CBD e-commerce company BSK Holdings
2 | Organigram Global shares recording of its OG investor session
3 | Canopy Growth sued for securities law violations
4 | 4Front provides update on management cease trade order application
Top Cannabis Stocks Apr. 18 to Apr. 24, 2025
1. T.TLRY | 5,784 views | Tilray Brands Inc.
2. T.LABS | 5,766 views | Medipharm Labs Corp.
3. T.CURA | 4,238 views | Curaleaf Holdings Inc.
4. T.WEED | 3,254 views | Canopy Growth Corp.
5. T.OGI | 593 views | Organigram Holdings Inc.
6. C.TGIF | 545 views | 1933 Industries Inc. Inc.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
6 days ago
- The Market Online
Cannabis Report: Growing beyond borders
Tilray Medical has become the first company to receive Italian authorization to distribute medical cannabis flower for therapeutic use. Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment. Medical cannabis flower, bottle and prescription. (Source: Adobe Stock) Click here for the full story. 1 | Simply Solventless Concentrates announces record quarterly gross revenue in its Q1 2025 financial results 2 | HYLQ signs letter of intent with Kinetiq Research to deliver diversified, high-conviction exposure to projects in the hyper liquid ecosystem 3 | High Tide marks Canada Day by launching summer long 'buy local' initiative Top Cannabis Stocks June 20 to June 26, 2025 1. | 9,388 views | Medipharm Labs Corp. 2. | 5,276 views | Canopy Growth Corp. 3. | 5,021 views | Tilray Brands Inc. 4. | 4,432 views | Curaleaf Holdings Inc. 5. | 627 views | Nextleaf Solutions Ltd. 6. | 517 views | Organigram Holdings Inc. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Cision Canada
26-06-2025
- Cision Canada
SIMPLY SOLVENTLESS ANNOUNCES RECORD "STATUS" BRAND MONTHLY SALES & REVOCATION OF MANAGEMENT CEASE TRADE ORDER
CALGARY, AB, /CNW/ - Simply Solventless Concentrates Ltd. (TSXV: HASH) (" SSC" or the " Company") is pleased to announce that its Status brand has achieved record monthly sales and increasing sales velocity. SSC is also pleased to advise that due to SSC filing its Q1 2025 financial statements, the related management discussion and analysis, and the related CEO and CFO certifications, (the " Filings"), the previously announced management cease trade order (" MCTO") under National Policy 12-203 – Management Cease Trade Orders (" NP 12-203") initially issued by the Alberta Securities Commission (" ASC"), the Company's principal regulator, on May 5, 2025, and subsequently updated by SSC through press releases issued on April 30, 2025, May 14, 2025, May 20, 2025, and June 2, 2025, has been revoked. Copies of the required Filings are available on the Company's SEDAR+ profile at Status Brand Launched in late 2024, SSC's Status brand, acquired as part of the ANC Inc. acquisition in October, 2024, continues to gain traction across Canada. Unit sales have increased by 115% since January 2025, and June 2025 marked the first month that the Status brand's sales exceeded $1.0 million. Status currently has 12 total product listings in Ontario and Alberta. The following 8 new product listings are launching in the coming months, bringing total Status product listings to 20: Ontario June: Bubble Bubble Liquid Diamond Infused Kief Coated Blunt. Alberta July: Grape Blast Liquid Diamond Infused Kief Coated Pre-Rolls. Alberta July: Mellonaire Liquid Diamond Infused Kief Coated Pre-Rolls. Alberta July: Tigers Bleed Liquid Diamond Infused Kief Coated Pre-Rolls. Ontario August/September: Lamborkiwi Cannagar. Ontario August/September: Bubble Bubble Cannagar. Ontario September/October: Lamborkiwi Liquid Diamond Disposable. Ontario September/October: Grape Blast Liquid Diamond Infused Kief Coated Blunt. With the success of Status, SSC's current suite of brands and products, including Astrolab, Frootyhooty, Roilty, and Lamplighter, and the upcoming launch of the legendary Sluggers brand in Canada (as previously announced), SSC is encouraged by the potential for organic revenue growth in the coming quarters. About Simply Solventless Concentrates Ltd. SSC is a public company incorporated under the Business Corporations Act (Alberta). SSC's mission is to provide pure, potent, terpene-rich ready to consume cannabis products to discerning cannabis consumers. For more information regarding SSC, please see Notice on Forward Looking Information This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "will", "estimates", "believes", "intends", "expects", "projected", "approximately" and similar expressions which are intended to identify forward-looking statements. More particularly and without limitation, this press release contains forward looking statements concerning Stats brand product launches, increasing velocity of Status SKUs, initial Sluggers product launches and revenue growth, and revenue growth of SSC's current brands and products. SSC cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of SSC, including expectations and assumptions concerning SSC, the timing and market acceptance of products, competition in SSC's markets, SSC's reliance on customers, fluctuations in interest rates, SSC's ability to maintain good relations with its customers, employees and other stakeholders, changes in law or regulations, SSC's ability to protect its intellectual property, as well as other risks and uncertainties, including those described in SSC's filings available on SEDAR+ at including its most recent annual information form. The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of SSC. The reader is cautioned not to place undue reliance on any forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release, and SSC does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Simply Solventless Concentrates Ltd.
Cision Canada
20-06-2025
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
